PE20010402A1 - Derivados de 1,5-dihidropirrol-2-ona sustituida - Google Patents
Derivados de 1,5-dihidropirrol-2-ona sustituidaInfo
- Publication number
- PE20010402A1 PE20010402A1 PE2000000761A PE0007612000A PE20010402A1 PE 20010402 A1 PE20010402 A1 PE 20010402A1 PE 2000000761 A PE2000000761 A PE 2000000761A PE 0007612000 A PE0007612000 A PE 0007612000A PE 20010402 A1 PE20010402 A1 PE 20010402A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- heteroaryl
- aryl
- cor8
- dihydropyrrolt
- Prior art date
Links
- 101100134927 Gallus gallus COR8 gene Proteins 0.000 abstract 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010011224 Cough Diseases 0.000 abstract 1
- 206010013654 Drug abuse Diseases 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- 208000007882 Gastritis Diseases 0.000 abstract 1
- 239000004471 Glycine Substances 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000019622 heart disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 208000014001 urinary system disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Pulmonology (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
Abstract
SE REFIERE A DERIVADOS DE 1,5-DIHIDROPIRROL-2-ONA DE FORMULA I, DONDE: X ES O, S, NR7; R1 ES H, OR11, SR11, COR8, CSR8, NR9R10, ALQUILO C1-C10, ARILO, HETEROARILO; R2 Y R3 SON H, F, Cl, Br, CF3, OR11, SR11, NR9R10, ALQUILO C1-C10, ARILO, HETEROARILO; R4 ES H, OH, OR11, SR11, COR8, COOR8, ALQUILO C1-C10, ARILO, HETEROARILO; R5 Y R6 SON H, O, OH, OR11, SR11, COR8, CSR8, COOR8, COCOR8, CONR9R10, CSNR9R10, ALQUILO C1-C10, ARILO, HETEROARILO, ENTRE OTROS. R7 ES H, OR11, SR11, COR8, COOR8, COCOR8, ENTRE OTROS; R8 ES H, OR11, SR11, NR9R10, ALQUILO C1-C10, ENTRE OTROS; R9 ES ALQUILO C1-C10, HETEROARILO, ARILO, ALQUILENO C1-C6, ENTRE OTROS; R10 ES ALQUILO C1-C10, HETEROARILO, ARILO; R11 ES ALQUILO C1-C10, ARILO, HETEROARILO, ENTRE OTROS; SON COMPUESTOS PREFERIDOS ACIDO 1-METIL-3-ACETAMIDO-5-ETOXIMETILENTETRAMICO, ACIDO 3-ACETAMIDO-5-ETOXIMETILENTETRAMICO, 5-BENCILIDEN-4-METOXI-3-NITROSO-1,5-DIHIDROPIRROL-2-ONA, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. EL COMPUESTO I TIENEN AFINIDAD POR EL PUNTO DE LIGADURA DE GLICINA DEL CANAL RECEPTOR NMDA Y PUEDE SER UTIL PARA EL TRATAMIENTO DE DOLORES, REACCIONES INFLAMATORIAS, ALERGICAS, DEPRESIONES, ABUSO DE FARMACOS, ALCOHOL, GASTRITIS, DIARREA, INCONTINENCIA URINARIA, AFECCIONES CARDIOVASCULARES, ENFERMEDADES DE LAS VIAS RESPIRATORIAS, TOS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19936719A DE19936719A1 (de) | 1999-08-06 | 1999-08-06 | Substituierte 1,5-Dihydropyrrol-2-on-Derivate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20010402A1 true PE20010402A1 (es) | 2001-05-05 |
Family
ID=7917172
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2000000761A PE20010402A1 (es) | 1999-08-06 | 2000-08-01 | Derivados de 1,5-dihidropirrol-2-ona sustituida |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US6642267B2 (es) |
| EP (1) | EP1200402B1 (es) |
| JP (1) | JP2003506437A (es) |
| KR (1) | KR20020025214A (es) |
| CN (1) | CN1378532A (es) |
| AR (1) | AR028848A1 (es) |
| AT (1) | ATE304530T1 (es) |
| AU (1) | AU782435B2 (es) |
| BR (1) | BR0013311A (es) |
| CA (1) | CA2381033A1 (es) |
| CO (1) | CO5200758A1 (es) |
| CZ (1) | CZ2002441A3 (es) |
| DE (2) | DE19936719A1 (es) |
| ES (1) | ES2248104T3 (es) |
| HK (1) | HK1046405A1 (es) |
| HU (1) | HUP0201937A3 (es) |
| IL (1) | IL147977A0 (es) |
| MX (1) | MXPA02001212A (es) |
| NO (1) | NO20020574L (es) |
| NZ (1) | NZ516988A (es) |
| PE (1) | PE20010402A1 (es) |
| PL (1) | PL353854A1 (es) |
| SK (1) | SK1702002A3 (es) |
| WO (1) | WO2001010833A1 (es) |
| ZA (1) | ZA200201788B (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1269482C (zh) * | 2001-05-18 | 2006-08-16 | 威克斯医药有限公司 | 钠离子通道阻断剂和阿片类镇痛剂在制备用于对哺乳动物进行协同镇痛的药物中的应用 |
| US7732162B2 (en) | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
| US9072662B2 (en) | 2004-03-29 | 2015-07-07 | Auris Medical Ag | Methods for the treatment of tinnitus induced by cochlear excitotoxicity |
| US20060063802A1 (en) | 2004-03-29 | 2006-03-23 | Matthieu Guitton | Methods for the treatment of tinnitus induced by cochlear excitotoxicity |
| US8268866B2 (en) | 2004-03-29 | 2012-09-18 | Matthieu Guitton | Methods for the treatment of tinnitus induced by cochlear excitotoxicity |
| EP2425846A1 (en) * | 2004-12-23 | 2012-03-07 | Voyager Pharmaceutical Corporation | Acetylcholinesterase Inhibitors and leuprolide acetate for the treatment of Alzheimer's disease |
| WO2007038949A1 (en) | 2005-09-28 | 2007-04-12 | Auris Medical Ag | Pharmaceutical compositions for the treatment of inner ear disorders |
| JP5379692B2 (ja) | 2006-11-09 | 2013-12-25 | プロビオドルグ エージー | 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体 |
| DK2091948T3 (da) | 2006-11-30 | 2012-07-23 | Probiodrug Ag | Nye inhibitorer af glutaminylcyclase |
| AU2008220785B2 (en) | 2007-03-01 | 2013-02-21 | Vivoryon Therapeutics N.V. | New use of glutaminyl cyclase inhibitors |
| US9656991B2 (en) | 2007-04-18 | 2017-05-23 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| MX2011001671A (es) * | 2008-08-12 | 2011-06-17 | Zinfandel Pharmaceuticals Inc | Metodo de identificacion de factores de riesgo de la enfermedad. |
| US8846315B2 (en) | 2008-08-12 | 2014-09-30 | Zinfandel Pharmaceuticals, Inc. | Disease risk factors and methods of use |
| EP2475428B1 (en) | 2009-09-11 | 2015-07-01 | Probiodrug AG | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
| JP6026284B2 (ja) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤 |
| EA022420B1 (ru) | 2010-03-10 | 2015-12-30 | Пробиодруг Аг | Гетероциклические ингибиторы глутаминилциклазы (qc, ec 2.3.2.5) |
| WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
| MX339844B (es) | 2011-01-10 | 2016-06-13 | Takeda Pharmaceuticals Co | Metodos y productos de farmaco para tratar enfermedad de alzheimer. |
| ES2570167T3 (es) | 2011-03-16 | 2016-05-17 | Probiodrug Ag | Derivados de benzimidazol como inhibidores de glutaminil ciclasa |
| KR102084185B1 (ko) * | 2013-08-29 | 2020-03-04 | 주식회사 대웅제약 | 테트라히드로사이클로펜타피롤 유도체 및 이의 제조방법 |
| US10708389B2 (en) * | 2016-12-06 | 2020-07-07 | Intelligrated Headquarters, Llc | Phased deployment of scalable real time web applications for material handling system |
| ES2812698T3 (es) | 2017-09-29 | 2021-03-18 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
| WO2025145182A1 (en) * | 2023-12-29 | 2025-07-03 | Case Western Reserve University | Selective inhibitors of t cell activation |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL258360A (es) * | 1960-11-25 | |||
| DE3434562A1 (de) * | 1984-09-20 | 1986-03-27 | Boehringer Mannheim Gmbh, 6800 Mannheim | Verwendung von pyrrothinderivaten |
| GB2170498A (en) * | 1985-02-04 | 1986-08-06 | Ici Plc | Processes for making fungicidal dithiolopyrrolones |
| GB2173499A (en) * | 1985-02-04 | 1986-10-15 | Ici Plc | Fungicidal dithiolopyrrolones |
| GB9210393D0 (en) * | 1992-05-15 | 1992-07-01 | Merck Sharp & Dohme | Therapeutic agents |
-
1999
- 1999-08-06 DE DE19936719A patent/DE19936719A1/de not_active Ceased
-
2000
- 2000-07-25 CA CA002381033A patent/CA2381033A1/en not_active Abandoned
- 2000-07-25 BR BR0013311-6A patent/BR0013311A/pt not_active IP Right Cessation
- 2000-07-25 SK SK170-2002A patent/SK1702002A3/sk not_active Application Discontinuation
- 2000-07-25 PL PL00353854A patent/PL353854A1/xx not_active Application Discontinuation
- 2000-07-25 JP JP2001515300A patent/JP2003506437A/ja not_active Withdrawn
- 2000-07-25 AU AU68279/00A patent/AU782435B2/en not_active Ceased
- 2000-07-25 CZ CZ2002441A patent/CZ2002441A3/cs unknown
- 2000-07-25 WO PCT/EP2000/007100 patent/WO2001010833A1/de not_active Ceased
- 2000-07-25 IL IL14797700A patent/IL147977A0/xx unknown
- 2000-07-25 KR KR1020027001608A patent/KR20020025214A/ko not_active Withdrawn
- 2000-07-25 MX MXPA02001212A patent/MXPA02001212A/es active IP Right Grant
- 2000-07-25 NZ NZ516988A patent/NZ516988A/en unknown
- 2000-07-25 AT AT00956273T patent/ATE304530T1/de active
- 2000-07-25 ES ES00956273T patent/ES2248104T3/es not_active Expired - Lifetime
- 2000-07-25 HU HU0201937A patent/HUP0201937A3/hu unknown
- 2000-07-25 HK HK02107776.3A patent/HK1046405A1/zh unknown
- 2000-07-25 DE DE50011178T patent/DE50011178D1/de not_active Expired - Lifetime
- 2000-07-25 CN CN00813944A patent/CN1378532A/zh active Pending
- 2000-07-25 EP EP00956273A patent/EP1200402B1/de not_active Expired - Lifetime
- 2000-07-31 AR ARP000103963A patent/AR028848A1/es not_active Application Discontinuation
- 2000-08-01 PE PE2000000761A patent/PE20010402A1/es not_active Application Discontinuation
- 2000-08-03 CO CO00058413A patent/CO5200758A1/es not_active Application Discontinuation
-
2002
- 2002-02-05 NO NO20020574A patent/NO20020574L/no not_active Application Discontinuation
- 2002-02-06 US US10/066,800 patent/US6642267B2/en not_active Expired - Fee Related
- 2002-03-04 ZA ZA200201788A patent/ZA200201788B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2248104T3 (es) | 2006-03-16 |
| BR0013311A (pt) | 2003-01-28 |
| NO20020574L (no) | 2002-03-25 |
| IL147977A0 (en) | 2002-09-12 |
| CO5200758A1 (es) | 2002-09-27 |
| US6642267B2 (en) | 2003-11-04 |
| HK1046405A1 (zh) | 2003-01-10 |
| US20020161033A1 (en) | 2002-10-31 |
| NZ516988A (en) | 2004-11-26 |
| EP1200402B1 (de) | 2005-09-14 |
| DE50011178D1 (de) | 2005-10-20 |
| NO20020574D0 (no) | 2002-02-05 |
| DE19936719A1 (de) | 2001-02-15 |
| JP2003506437A (ja) | 2003-02-18 |
| SK1702002A3 (en) | 2002-07-02 |
| ZA200201788B (en) | 2003-08-27 |
| WO2001010833A1 (de) | 2001-02-15 |
| CA2381033A1 (en) | 2001-02-15 |
| AR028848A1 (es) | 2003-05-28 |
| MXPA02001212A (es) | 2002-07-02 |
| CZ2002441A3 (cs) | 2002-05-15 |
| KR20020025214A (ko) | 2002-04-03 |
| HUP0201937A3 (en) | 2002-12-28 |
| PL353854A1 (en) | 2003-12-01 |
| AU782435B2 (en) | 2005-07-28 |
| EP1200402A1 (de) | 2002-05-02 |
| AU6827900A (en) | 2001-03-05 |
| CN1378532A (zh) | 2002-11-06 |
| HUP0201937A2 (en) | 2002-10-28 |
| ATE304530T1 (de) | 2005-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20010402A1 (es) | Derivados de 1,5-dihidropirrol-2-ona sustituida | |
| PE20030702A1 (es) | Inhibidores de pde9 para tratamiento de transtornos cardiovasculares | |
| CY1120169T1 (el) | Παραγωγο αμιδιου και φαρμακο | |
| IS2598B (is) | Þíenópýrimidíndíón og notkun þeirra í mótun sjálfnæmissjúkdóma | |
| SE0104334D0 (sv) | Therapeutic agents | |
| ES2059069T3 (es) | Nuevos derivados de 1-alcoxi-(2-acilamino-etil)-naftalenos y su procedimiento de preparacion. | |
| RU2003134544A (ru) | Амиды антраниловой кислоты, способы их получения, их применение в качестве антиаритмических средств, а также содержащие их фармацевтические композиции | |
| SE9903760D0 (sv) | New compounds | |
| CA2436846A1 (en) | Thioether substituted imidazoquinolines | |
| DE60039359D1 (de) | Amide als pyruvatdehydrogenaseinhibitoren | |
| RU2008141850A (ru) | Жидкий фармацевтический препарат с немедленным высвобождением | |
| DE69229442D1 (de) | Substituierte dibenzooxazepin-verbindungen, pharmazeutische zusammensetzungen und verfahren zur verwendung | |
| SE0201659D0 (sv) | Modified release pharmaceutical formulation | |
| RU2002110328A (ru) | Препарат замещенных бензимидазолов | |
| SE9903997D0 (sv) | New compounds | |
| AP9901578A0 (en) | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents. | |
| CA2425199A1 (en) | Formulation of substituted benzimidazoles | |
| ATE366107T1 (de) | Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen | |
| RU2007122406A (ru) | Производные тетралина и индана и их применения в качестве антагонистов 5-нт | |
| EP1256581A4 (en) | PREVENTIVE OR THERAPEUTIC AGENTS FOR GASTRICHES OR ESOPHAGEAL REGURGITATION | |
| RU2007123251A (ru) | Производные хромана и их применение в качестве лигандов 5-нт рецептора | |
| PT95990A (pt) | Processo para a preparacao de novos derivados do tiofeno | |
| SE0104333D0 (sv) | Therapeutic agents | |
| DE69930621D1 (de) | Medizinische zusammensetzungen zur unmittelbaren freisetzung bei oraler anwendung | |
| BG106851A (en) | Calcium dicarboxylate ethers, methods of making same, and their use for the treatment of vascular disease and diabetes therewith |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |